Medical - Care Facilities
Compare Stocks
4 / 10Stock Comparison
CCRN vs MAN vs KELYA vs TBI
Revenue, margins, valuation, and 5-year total return — side by side.
Staffing & Employment Services
Staffing & Employment Services
Staffing & Employment Services
CCRN vs MAN vs KELYA vs TBI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Care Facilities | Staffing & Employment Services | Staffing & Employment Services | Staffing & Employment Services |
| Market Cap | $423M | $1.41B | $349M | $182M |
| Revenue (TTM) | $761M | $17.96B | $3.09B | $1.25B |
| Net Income (TTM) | $-99M | $-13M | $-266M | $-53M |
| Gross Margin | 18.2% | 16.7% | 26.3% | 28.4% |
| Operating Margin | -0.9% | 0.8% | -2.8% | -2.6% |
| Forward P/E | 133.8x | 8.3x | 11.0x | — |
| Total Debt | $2M | $2.39B | $159M | $171M |
| Cash & Equiv. | $109M | $871M | $33M | $25M |
CCRN vs MAN vs KELYA vs TBI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Cross Country Healt… (CCRN) | 100 | 215.7 | +115.7% |
| ManpowerGroup Inc. (MAN) | 100 | 44.0 | -56.0% |
| Kelly Services, Inc. (KELYA) | 100 | 64.7 | -35.3% |
| TrueBlue, Inc. (TBI) | 100 | 38.9 | -61.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CCRN vs MAN vs KELYA vs TBI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CCRN is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- -10.5% 10Y total return vs MAN's -30.8%
- Lower volatility, beta 0.78, Low D/E 0.7%, current ratio 3.78x
- Beta 0.78, current ratio 3.78x
- Beta 0.78 vs TBI's 1.13, lower leverage
MAN carries the broadest edge in this set and is the clearest fit for value and quality.
- Better valuation composite
- -0.1% margin vs CCRN's -13.0%
- 4.7% yield, vs KELYA's 3.2%, (2 stocks pay no dividend)
- -0.1% ROA vs CCRN's -19.8%, ROIC 5.6% vs -0.9%
KELYA is the clearest fit if your priority is income & stability.
- Dividend streak 5 yrs, beta 1.01, yield 3.2%
TBI is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 3.1%, EPS growth 61.4%, 3Y rev CAGR -10.5%
- 3.1% revenue growth vs CCRN's -21.6%
- +51.0% vs MAN's -17.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 3.1% revenue growth vs CCRN's -21.6% | |
| Value | Better valuation composite | |
| Quality / Margins | -0.1% margin vs CCRN's -13.0% | |
| Stability / Safety | Beta 0.78 vs TBI's 1.13, lower leverage | |
| Dividends | 4.7% yield, vs KELYA's 3.2%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +51.0% vs MAN's -17.0% | |
| Efficiency (ROA) | -0.1% ROA vs CCRN's -19.8%, ROIC 5.6% vs -0.9% |
CCRN vs MAN vs KELYA vs TBI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
CCRN vs MAN vs KELYA vs TBI — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MAN leads in 3 of 6 categories
CCRN leads 2 • KELYA leads 0 • TBI leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
MAN leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MAN is the larger business by revenue, generating $18.0B annually — 23.6x CCRN's $761M. MAN is the more profitable business, keeping -0.1% of every revenue dollar as net income compared to CCRN's -13.0%. On growth, MAN holds the edge at +7.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $761M | $18.0B | $3.1B | $1.2B |
| EBITDAEarnings before interest/tax | $9M | $236M | -$54M | -$10M |
| Net IncomeAfter-tax profit | -$99M | -$13M | -$266M | -$53M |
| Free Cash FlowCash after capex | $41M | -$161M | $66M | -$60M |
| Gross MarginGross profit ÷ Revenue | +18.2% | +16.7% | +26.3% | +28.4% |
| Operating MarginEBIT ÷ Revenue | -0.9% | +0.8% | -2.8% | -2.6% |
| Net MarginNet income ÷ Revenue | -13.0% | -0.1% | -8.6% | -4.3% |
| FCF MarginFCF ÷ Revenue | +5.4% | -0.9% | +2.1% | -4.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | +7.1% | -100.0% | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -6.0% | +36.2% | -2.1% | -37.5% |
Valuation Metrics
MAN leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, MAN's 9.0x EV/EBITDA is more attractive than TBI's 160.0x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $423M | $1.4B | $349M | $182M |
| Enterprise ValueMkt cap + debt − cash | $317M | $2.9B | $475M | $329M |
| Trailing P/EPrice ÷ TTM EPS | -4.47x | -104.90x | -1.34x | -3.73x |
| Forward P/EPrice ÷ next-FY EPS est. | 133.84x | 8.28x | 10.96x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 23.75x | 9.02x | — | 160.03x |
| Price / SalesMarket cap ÷ Revenue | 0.40x | 0.08x | 0.08x | 0.11x |
| Price / BookPrice ÷ Book value/share | 1.31x | 0.69x | 0.35x | 0.65x |
| Price / FCFMarket cap ÷ FCF | 10.55x | — | 3.06x | — |
Profitability & Efficiency
MAN leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
MAN delivers a -0.6% return on equity — every $100 of shareholder capital generates $-1 in annual profit, vs $-27 for CCRN. CCRN carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to MAN's 1.16x. On the Piotroski fundamental quality scale (0–9), CCRN scores 6/9 vs MAN's 1/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -27.1% | -0.6% | -24.6% | -18.7% |
| ROA (TTM)Return on assets | -19.8% | -0.1% | -11.3% | -8.1% |
| ROICReturn on invested capital | -0.9% | +5.6% | -4.0% | -5.2% |
| ROCEReturn on capital employed | -0.8% | +6.2% | -4.3% | -5.3% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 1 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.01x | 1.16x | 0.16x | 0.62x |
| Net DebtTotal debt minus cash | -$106M | $1.5B | $126M | $146M |
| Cash & Equiv.Liquid assets | $109M | $871M | $33M | $25M |
| Total DebtShort + long-term debt | $2M | $2.4B | $159M | $171M |
| Interest CoverageEBIT ÷ Interest expense | -1.39x | 1.98x | -12.07x | -46.19x |
Total Returns (Dividends Reinvested)
CCRN leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CCRN five years ago would be worth $7,746 today (with dividends reinvested), compared to $2,130 for TBI. Over the past 12 months, TBI leads with a +51.0% total return vs MAN's -17.0%. The 3-year compound annual growth rate (CAGR) favors KELYA at -13.0% vs TBI's -26.4% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +62.4% | +1.2% | +13.1% | +36.6% |
| 1-Year ReturnPast 12 months | -5.4% | -17.0% | -12.2% | +51.0% |
| 3-Year ReturnCumulative with dividends | -44.3% | -46.4% | -34.2% | -60.2% |
| 5-Year ReturnCumulative with dividends | -22.5% | -64.9% | -58.3% | -78.7% |
| 10-Year ReturnCumulative with dividends | -10.5% | -30.8% | -33.0% | -68.4% |
| CAGR (3Y)Annualised 3-year return | -17.7% | -18.8% | -13.0% | -26.4% |
Risk & Volatility
CCRN leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CCRN is the less volatile stock with a 0.78 beta — it tends to amplify market swings less than TBI's 1.13 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CCRN currently trades 87.3% from its 52-week high vs MAN's 64.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.78x | 1.03x | 1.01x | 1.13x |
| 52-Week HighHighest price in past year | $14.99 | $47.34 | $14.94 | $7.78 |
| 52-Week LowLowest price in past year | $7.43 | $25.15 | $7.98 | $3.18 |
| % of 52W HighCurrent price vs 52-week peak | +87.3% | +64.3% | +64.9% | +77.2% |
| RSI (14)Momentum oscillator 0–100 | 53.1 | 47.1 | 63.7 | 83.2 |
| Avg Volume (50D)Average daily shares traded | 552K | 1.1M | 361K | 386K |
Analyst Outlook
Evenly matched — MAN and KELYA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: CCRN as "Hold", MAN as "Hold", KELYA as "Buy", TBI as "Buy". Consensus price targets imply 54.6% upside for KELYA (target: $15) vs -18.9% for CCRN (target: $11). For income investors, MAN offers the higher dividend yield at 4.71% vs KELYA's 3.23%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $10.61 | $37.86 | $15.00 | $5.75 |
| # AnalystsCovering analysts | 14 | 29 | 5 | 10 |
| Dividend YieldAnnual dividend ÷ price | — | +4.7% | +3.2% | — |
| Dividend StreakConsecutive years of raises | 1 | 0 | 5 | 0 |
| Dividend / ShareAnnual DPS | — | $1.43 | $0.31 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.6% | +2.7% | +3.5% | +0.6% |
MAN leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). CCRN leads in 2 (Total Returns, Risk & Volatility). 1 tied.
CCRN vs MAN vs KELYA vs TBI: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is CCRN or MAN or KELYA or TBI a better buy right now?
For growth investors, TrueBlue, Inc.
(TBI) is the stronger pick with 3. 1% revenue growth year-over-year, versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). Analysts rate Kelly Services, Inc. (KELYA) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CCRN or MAN or KELYA or TBI?
Over the past 5 years, Cross Country Healthcare, Inc.
(CCRN) delivered a total return of -22. 5%, compared to -78. 7% for TrueBlue, Inc. (TBI). Over 10 years, the gap is even starker: CCRN returned -10. 5% versus TBI's -68. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CCRN or MAN or KELYA or TBI?
By beta (market sensitivity over 5 years), Cross Country Healthcare, Inc.
(CCRN) is the lower-risk stock at 0. 78β versus TrueBlue, Inc. 's 1. 13β — meaning TBI is approximately 46% more volatile than CCRN relative to the S&P 500. On balance sheet safety, Cross Country Healthcare, Inc. (CCRN) carries a lower debt/equity ratio of 1% versus 116% for ManpowerGroup Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — CCRN or MAN or KELYA or TBI?
By revenue growth (latest reported year), TrueBlue, Inc.
(TBI) is pulling ahead at 3. 1% versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). On earnings-per-share growth, the picture is similar: TrueBlue, Inc. grew EPS 61. 4% year-over-year, compared to -427. 4% for Kelly Services, Inc.. Over a 3-year CAGR, MAN leads at -3. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CCRN or MAN or KELYA or TBI?
ManpowerGroup Inc.
(MAN) is the more profitable company, earning -0. 1% net margin versus -9. 0% for Cross Country Healthcare, Inc. — meaning it keeps -0. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MAN leads at 1. 3% versus -1. 7% for TBI. At the gross margin level — before operating expenses — TBI leads at 21. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CCRN or MAN or KELYA or TBI more undervalued right now?
On forward earnings alone, ManpowerGroup Inc.
(MAN) trades at 8. 3x forward P/E versus 133. 8x for Cross Country Healthcare, Inc. — 125. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for KELYA: 54. 6% to $15. 00.
07Which pays a better dividend — CCRN or MAN or KELYA or TBI?
In this comparison, MAN (4.
7% yield), KELYA (3. 2% yield) pay a dividend. CCRN, TBI do not pay a meaningful dividend and should not be held primarily for income.
08Is CCRN or MAN or KELYA or TBI better for a retirement portfolio?
For long-horizon retirement investors, Kelly Services, Inc.
(KELYA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 01), 3. 2% yield). Both have compounded well over 10 years (KELYA: -33. 0%, TBI: -68. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CCRN and MAN and KELYA and TBI?
These companies operate in different sectors (CCRN (Healthcare) and MAN (Industrials) and KELYA (Industrials) and TBI (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: CCRN is a small-cap quality compounder stock; MAN is a small-cap income-oriented stock; KELYA is a small-cap income-oriented stock; TBI is a small-cap quality compounder stock. MAN, KELYA pay a dividend while CCRN, TBI do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.